Amifostine has also been studied to reduce nephrotoxicity with cisplatin. A study administering amifostine to patients with ovarian cancer who were receiving high doses of cisplatin (100mg/m2) demonstrated a reduction in the incidence of nephrotoxicity (defined as a ≥40% reduction in creatinine clearance) from 33% to 10% with the addition of amifostine. Amifostine is recommended by the American Society of Clinical Oncology for prevention of cisplatin-induced nephrotoxicity in patients with ovarian or non-small cell lung cancer who are receiving doses of cisplatin of 100mg/m2 or higher, however there is not data to support use of amifostine for this purpose in other settings.2
1. Hensley ML, et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. J Clin Oncol 2009; 27(1):127-145.
2. Cisplatin prescribing information. WG Critical Care, LLC. Paramus, NJ. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdf Revised February 2015. Accessed July 14, 2015.